A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " EPS Corporation

EPS Corporation

Table of Contents

EPS Corporation conducts non-clinical studies through its consolidated subsidiary, L.S.G. Corporation. Leveraging its extensive experience and IT capabilities, the research institute provides integrated support from testing to data management. With a reliability-focused research system, EPS Corporation supports clients in achieving high-quality development outcomes.

Features of EPS Corporation’s Contract Non-Clinical Study Services

In-house non-clinical testing capabilities within the group

EPS Corporation is a contract research organization offering a wide range of non-clinical study services. Through its consolidated subsidiary, L.S.G. Corporation, EPS Corporation provides pharmacology and safety studies, among other non-clinical evaluations.

Its research facilities are designed to comply with GLP and other reliability standards, ensuring high-quality support for critical preclinical evaluation processes.

Expertise in CSV support for pharmaceuticals and medical devices

EPS Corporation offers system validation (CSV) support essential for pharmaceutical and medical device R&D to ensure data integrity in non-clinical studies. The company is also capable of supporting compliance with international regulations such as FDA 21 CFR Part 11, providing consulting aligned with global standards—including documentation for regulatory submission and operational design in accordance with GxP.

Knowledge in IT implementation for non-clinical studies

To enhance data management and reliability in non-clinical studies, EPS Corporation also focuses on IT system integration.

Based on its expertise in electronic records/electronic signatures (ER/ES), LIMS, and equipment integration, EPS provides comprehensive support from system implementation to full-scale operation. By reinforcing quality assurance frameworks through IT solutions, the company achieves both operational efficiency and data accuracy.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of disease models owned by EPS Corporation

No case studies were available on the official website.

Non-clinical study examples of EPS Corporation

No case studies were available on the official website.

EPS Corporation Company Information

Address	Tsuruya Building, 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo
Tel	03-5684-7797
Website	https://www.eps.co.jp/ja/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us